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convened a Consultation of experts on male lower urinary tract symptoms. The Consultation
assigned standardized levels of evidence and grades of recommendation to various studies of
nocturia epidemiology, pathophysiology, assessment, and treatment.RESULTS Evidence review and consensus recommendations were made in the areas of epidemiology,
pathophysiology, assessment, and treatment.CONCLUSION The review presents a condensed summary of the International Consultations on Urological
DiseaseseSociete Internationale d’Urologie evaluation of nocturia, which offers contemporaneous
expert consensus on this topic, with an assessment algorithm emphasizing the potential contri-
bution of systemic conditions to the symptom. UROLOGY -: -e-, 2015.  2015 Elsevier Inc.octuria, one of the storage-type lower urinary
tract symptoms (LUTS), is deﬁned by theNInternational Continence Society as the
complaint of waking at night to void.1 Despite this simple
deﬁnition, nocturia is idiosyncratic in a number of ways.
For example, nocturia of equivalent frequency causes
markedly different reductions in quality of life (QoL) for
different people. Consequently, QoL improvements
deriving from treatment responses may differ between
study populations. In some patients, nocturia progresses
slowly, whereas in others, it remains stable or regresses with
time. Finally, nocturia is multifactorial in etiology, making
both assessment and treatment a potential challenge. Thisashim is a consultant for Allergan, American Medical
J. Drake is a consultant for Allergan, Astellas, and
a consultant for Ferring, Pﬁzer, Astellas, Allergan,
remaining authors declare that they have no relevant
y, SUNY Downstate Medical Center, Brooklyn, NY;
ctice, University of Groningen, University Medical
he Netherlands; the University of Bristol and Bristol
ospital, Bristol, United Kingdom; the New England
MA; the Department of Urology, Helsinki University
of Helsinki, Helsinki, Finland; the Departments of
versity of Helsinki and Helsinki University Hospital,
partment of Urology, Shizuoka General Hospital,
rcus J. Drake, D.M., F.R.C.S.(Urol.), University of
itute, Southmead Hospital, Bristol BS10 5NB, United
bui.ac.uk
4, accepted (with revisions): February 17, 2015
hchallenge is an especially important one, however, as
nocturia may indicate serious underlying illness. Illnesses
such as cardiovascular, renal, or endocrine disease can
disrupt water and salt homeostasis, resulting in increased
production of urine.2 For this reason, even one nightly
void may be considered a progression from no nocturia and
thus an opportunity for secondary prevention. In such
contexts, where the pathophysiology of nocturia is not in
the lower urinary tract but reﬂecting systemic disease,
alluding to it as LUTS are potentially misleading.
The body of literature describing the evaluation and
management ofnocturia has expanded at a rapid rate. For this
reason, in 2012, the International Consultations on Uro-
logical Diseases (ICUD) partnered with the Societe Inter-
nationale d’Urologie (SIU) to convene a Consultation on
male LUTS. The goal of this Consultation was to use
established criteria to assign objective levels of evidence
(LOEs, 1 through 4) and grades of recommendation (GORs,
A through D) to the most salient research in the ﬁeld.3 The
purpose of this review is to present a condensed summary of
the ICUD-SIU evaluation of nocturia, incorporating addi-
tional subsequent panel review of the evidence base, which
offers contemporaneous expert consensus on this topic. LOEs
and GORs are presented here as the verbatim conclusions of
the ICUD-SIU panel, with more detailed descriptions pub-
lished elsewhere.4Wherepublished evidencewas found tobe
sparse, but the committee considered a recommendationwas





Studies of nocturia prevalence have demonstrated that it
is relatively common in both genders and all age groups.
For example, in the population-based Finnish National
Nocturia and Overactive Bladder Study, 1 of 8 men and
women 18-79 years old reported at least 2 voids per
night.5 Among young respondents, nocturia was more
common in women than men, but this gender difference
disappeared after middle age.
Incidence
The incidence of nocturia is not well understood, as the
required longitudinal studies are difﬁcult to perform. In
the community-based Krimpen study, for example, noc-
turia was assessed longitudinally with frequency-volume
charts over a period of several years.6 Overall incidence
and remission rates for nocturia 2 voids per night after
2 years were 24% and 37%, respectively. Considerable
ﬂuctuation was noted at different study time points.
Bother and Impact on Quality of Life
Sleep disturbance is an important cause of the increased
morbidity that is associated with nocturia. However, one
nightly void does not appear to be sufﬁciently disruptive
to cause signiﬁcant bother in most patients. In the
Finnish National Nocturia and Overactive Bladder
Study, for example, the majority of people reported
having bother when the number of nocturia episodes was
2, and 2 voids per night was associated with an impaired
Health Related Quality of Life. Two nocturia episodes
impaired Health Related Quality of Life compared with
those with no nocturia.7
Impact of Nocturia: Falls, Fractures, Mortality, and
Productivity
Much of the increased mortality associated with nocturia
may be due to the risk of hipfracture in patients who
frequently wake to void. Interestingly, in a study of men
aged 40-80 years, nocturia 2 voids per night was an age-
independent risk factor for hip fracture.8
Conclusions
The ICUD committee considered that nocturia is a
highly prevalent symptom, with similar overall preva-
lence in both genders. Prevalence increases more
markedly with age in men. The literature on the inci-
dence of nocturia remains relatively sparse. Incidence of
nocturia increases with age, but signiﬁcant short-term
ﬂuctuation in nocturia severity in individuals makes
studies on incidence challenging. Two or more episodes
of nocturia per night constitutes clinically meaningful
nocturia severity in the general population, affecting
QoL and perceived health, whereas a single episode
usually does not. Nocturia has been suggested to in-
crease risk of falls, fractures, death, and impaired
productivity.42Recommendations
The ICUD committee considered that epidemiologic
studies need to use strictly deﬁned and clearly stated
criteria of terminology and assessment. Approaches to
identify intraindividual variation and other confound-
ing inﬂuences need to be considered. Longitudinal
studies using high-quality methodology remain a priority
requirement. Nocturia of twice or more per night may
be a threshold of clinical signiﬁcance in the general
population. However, this threshold is not irrefutably
established and should not be extrapolated to sub-
populations. Research into all grades of nocturia severity
may yield information of clinical relevance.4
PATHOPHYSIOLOGY
Classiﬁcation and Risk Factors
Nocturia may be divided into the following 5 causative
categories:
(1) Bladder storage problems,
(2) Twenty-four-hour (global) polyuria (>40 mL/kg
urine output over a 24-hour period),
(3) Nocturnal polyuria1 (NP; nocturnal output exceeding
20% of 24-hour urine output in the young, or 33% of
urine output in people aged >65 years),
(4) Sleep disorders,
(5) Mixed etiology.
Examples of bladder storage problems include overactive
bladder (OAB) and urinary tract infection. Global polyuria
is commonly caused by polydipsia and by conditions such as
diabetes insipidus. NP is seen with peripheral edema and
circadian defects in arginine vasopressin secretion, among
many other conditions.2 Sleep disorders may be primary or
secondary. Nocturia of mixed etiology is caused by com-
binations of any of the aforementioned. A summary of the
ICUD-SIU conclusions regarding common risk factors for
nocturia is presented in Table 1.
Conclusions and Recommendations
The ICUD committee considered that the pathophysi-
ology of nocturia can be divided into the following 5
categories and associated with several risk factors (LOE 2,
GOR B): (1) bladder storage problems, (2) NP, (3) global
polyuria, (4) sleep disorders, and (5) mixed mechanisms.
Research into pathophysiology remains a priority.
Mechanisms underlying nocturia are poorly understood.
Establishing why some patients manifest nocturia and not
others with apparently similar predisposing factors, basic
research into age-related circadian rhythms, effects on
sleep quality, and the relationship between nocturia and
restorative stages of sleep are a priority.4
ASSESSMENT
Components of clinical assessment of nocturia are pre-
sented in Figure 1 and Table 2.UROLOGY - (-), 2015
Table 1. Representative studies demonstrating common risk factors for nocturia





Tikkinen et al42 3727 Half of the men with BPH reported
nocturia of 2 voids/night
Depression Asplund et al43 1375 Population-based study that demonstrated
a signiﬁcant association between major
depression and nocturia
HTN and CAD Yoshimura et al44 1856 HTN and CAD were both associated with
nocturia, though, with a modest effect size
Neurologic disease DasGupta and
Fowler45
n/a Review of evidence linking multiple sclerosis
to bladder dysfunction, including nocturia
Menopause and
hormonal therapy
Tikkinen et al46 2002 Parity, postpartum, and postmenopausal
periods were associated with nocturia
NP Torimoto et al47 1632 Demonstrated association between lower
extremity edema and nocturnal urine volume,
providing mechanistic basis for NP
Obesity and diabetes Fitzgerald et al48 5506 On multivariate regression, nocturia was
associated with both type 2 diabetes and
increased body mass index
Overactive bladder and
detrusor overactivity
Krystal et al49 24 Nocturnal cystometrogram evidence of
temporal relationship between nocturnal
detrusor overactivity and night-time voiding
Pelvic surgery Thakar et al50 279 Women reported fewer nightly voids after total
or subtotal abdominal hysterectomy
Alling et al51 1051 In a population-based study, history of
hysterectomy was associated with nocturia
PCa Tikkinen et al42 3727 Over 70% of men with PCa reported at least
2 voids/night, although it is unclear if such
men are simply being screened more
carefully, or if the 2 conditions are causally
related
Lifestyle Coffee and alcohol Tikkinen et al42 3727 No association between consumption of either
substance and nocturia
Smoking Tikkinen et al42 3727 No association between smoking and nocturia
Physical activity Soda et al52 56 Prospective study demonstrating a decrease in
nocturnal voids after multicomponent lifestyle




Fitzgerald et al48 5506 Higher odds of nocturia for black and Hispanic
study participants vs whites
BPH, benign prostatic hyperplasia; CAD, coronary artery disease; HTN, hypertension; NP, nocturnal polyuria; PCa, prostate cancer.Conclusions and Recommendations
The ICUD committee considered that validated symp-
tom questionnaires are recommended as tools for initial
and treatment response evaluation in the clinical setting
(grade C). Questionnaires are unsuitable for the estima-
tion of nocturnal voiding frequency (LOE 4, grade C).
Nocturia-speciﬁc QoL questionnaires can be used to
determine the impact of nocturia on QoL (LOE 4, grade
C). Urinary diaries are essential in the analysis of noc-
turia (LOE 4, grade C). The International Consultation
on Incontinence Questionnaire (ICIQ) bladder diary
has been developed according to methodological
requirements for assessment tools and has proceeded
through contextual validations (LOE 2, grade B).9
Medication review is an important part of nocturia
clinical assessment (grade A). Physical examination, ﬂow
rate testing, and urinalysis as relevant to assessment of
LUTS help identify potential contributory mechanisms
in some cases of nocturia (grade C). Postvoid residual
measurement is directly relevant to nocturia (grade C).
Routine use of invasive urodynamics, such as ﬁllingUROLOGY - (-), 2015cystometry and pressure ﬂow study, is not recommended
(grade D). Blood chemistry examination is optional
(grade CwD). Radiologic examinations or cystoscopy
should only be used where indicated by the medical
context, such as suspected malignant disease (grade D).4TREATMENT
Selected studies that were assigned LOEs by the ICUD-
SIU Consultation are brieﬂy described. A particular
issue in these studies is the extent to which any reduction
in nocturia could be considered clinically beneﬁcial.
Small reductions in nocturia severity as compared against
a control group could be statistically signiﬁcant but may
not be regarded as clinically signiﬁcant. This is particu-
larly the case if reduction compared with placebo is <0.5
episode per night. Nonetheless, it should be remembered
that statistical analysis is derived from the full population.
A small overall change could reﬂect varied responses in
the population, with some (“responders”) seeing a clini-
cally useful reduction and others seeing no change or only3
marginal reduction. Furthermore, placebo responses can
be comparatively large, which can obscure detection of
therapeutic response. Thus, a small additional reduction
in the overall study population does not preclude the
possibility that some patients could get useful beneﬁt from
an intervention. Most published studies were not clear on
whether the results could indicate the presence of a
subgroup of responders, and this is an area in which future
research publications should be explicit.
Conservative Management
Behavioral Modiﬁcation With Biofeedback. Burgio et al
conducted a randomized controlled trial (RCT) of 143
men with bladder outlet obstruction (BOO) and OAB
who had failed alpha-blocker therapy.10 Patients were
assigned to 8 weeks of behavioral therapy or oxybutynin.
Behavioral therapy reduced nocturia by 0.7 voids per
night, as compared with 0.32 voids per night for oxy-
butynin (P ¼ .05; LOE 3).
Song et al randomized 139 women with OAB and
nocturia to 12 weeks of bladder training, tolterodine, or
both.11 Nocturia decreased by 56% in the bladder
training group, 65% in the tolterodine group, and 66%
for both (P <.05; LOE 3).
Conclusions. The ICUD committee considered that
lifestyle changes and behavioral modiﬁcation are nonin-
vasive conservative methods that can successfully reduce
the number of nocturia episodes (LOE 3). Behavioral
modiﬁcation in conjunction with antimuscarinic phar-
macotherapy is more effective at reducing nocturia epi-
sodes than either method alone (LOE 3).4 However,
larger studies may be necessary to support this latter
ﬁnding.
Recommendations. The ICUD committee considered
that lifestyle changes, such as reducing intake of caffeine
and alcohol, limiting night-time ﬂuid intake, and
improving sleep hygiene, are effective methods that help
reduce nocturnal urine volume and episodes of nocturia
(GOR C). Consider using bladder training in conjunc-
tion with antimuscarinic medication (GOR C).4
Pharmacotherapy
5-Alpha Reductase Inhibitors. A recent systematic re-
view summarized the evidence of 23 RCTs encompassing
21,945 men to assess the efﬁcacy and risks of ﬁnasteride vs
placebo for LUTS associated with benign prostatic
enlargement (BPE).4 Although ﬁnasteride did signiﬁ-
cantly improve some LUTS, no signiﬁcant effect was seen
on nocturia in either short- or long-term use for the
overall cohort. Men aged >70 years did apparently see a
reduction in nocturia in 1 study, but the modest reduc-
tion compared with placebo (0.29 vs 0.11, respec-
tively) means the clinical beneﬁt was marginal.4
Conclusions. The ICUD committee considered that
ﬁnasteride does not reduce nocturia episodes in men.4Finasteride may improve nocturia in men with LUTS
aged 70 years (GOR C).4
Selective Alpha-1 Adrenergic Antagonists. Roehrborn
et al pooled the results of 3 RCTs of patients with BPE
who were randomized to receive alfuzosin or placebo.12
The treatment and placebo groups experienced
reductions of 1.1 and 0.8 voids per night, respectively
(P <.05; LOE 1).
Johnson et al performed an RCT of 3047 men with
LUTS suggestive of BPE who were assigned to receive
doxazosin alone, ﬁnasteride alone, combination therapy,
or placebo.13 At 4-year follow-up, rates of self-reported
nightly nocturia episodes were reduced in the doxazosin
and combination groups as compared with those of pla-
cebo (P <.05; LOE 1). In a separate study, Johnson et al
performed a secondary analysis of data from the VA
Cooperative Study Program Trial.14 In that trial, 1229
men with benign prostatic hyperplasia aged 45-80 years
were assigned to treatment with terazosin, ﬁnasteride, a
combination, or placebo. Terazosin and combination
therapy were the most effective, although the advantage
of terazosin over placebo was only 0.3 voids per night
(LOE 1).
Chapple et al randomized 955 men with LUTS to
receive silodosin, tamsulosin, or placebo for 12 weeks.15
Only silodosin signiﬁcantly reduced nocturia vs placebo,
but the absolute value of the difference in the study
population was modest (0.9 vs 0.7 voids per night;
P ¼ .0013; LOE 1).
Conclusions. The ICUD committee considered that the
majority of studies were undertaken in the context of men
with LUTS and presumed BPE, and assessment used the
IPSS, which has limitations in respect of evaluation of
nocturia. Evaluation of secondary outcome measures
could introduce type I errors (false-positive relationships).
Alfuzosin, doxazosin, naftopidil, silodosin, tamsulosin,
and terazosin are more effective than placebo at reducing
number of nocturia episodes in patients with BPE (LOE
1), but the extent of reduction was small in the overall
study populations. Administering an alternative alpha-
adrenergic antagonist may achieve improvement if noc-
turia fails to improve sufﬁciently with the ﬁrst drug tried
(LOE 3). Studies comparing efﬁcacy between agents need
to take into account dose equivalence and population
studied. Improving nocturia is an important factor for
improving overall QoL.4
Recommendations. The ICUD committee considered that
alpha-adrenergic antagonists may be offered to men with
nocturia in association with LUTS and BPE (GOR A). In
the event of insufﬁcient response to an alpha-adrenergic
antagonist, another may be offered (GOR C).4
Combination Therapy. 5-Alpha Reductase Inhibitor þ
Selective Alpha-1 Adrenergic Antagonist. Johnson et al
performed an RCT of 3047 men with LUTS suggestive of
BPE who were randomly assigned to receive doxazosin,UROLOGY - (-), 2015
Figure 1. Summary diagram for assessment of male nocturia patients based on potential mechanisms. CNS, central nervous
system; LUT, lower urinary tract; LUTS, lower urinary tract symptoms; OAB, overactive bladder. (Color version available online.)ﬁnasteride, combination therapy, or placebo.13 At 4-year
follow-up, rates of self-reported nightly nocturia episodes
were reduced in the doxazosin and combination groups as
compared with those of placebo (P <.05), as described
previously (LOE 1).
Antimuscarinic þ Alpha-1 Adrenergic Antagonist. Kaplan
et al studied the efﬁcacy of tolterodine extended release
(ER), tamsulosin, or both, as compared with that of
placebo for the treatment of men with both BPE and
OAB.16 For the 879 men enrolled in this randomized
study, only those who received combination therapy
experienced a signiﬁcant reduction in voids per night
(0.59 vs 0.39 episodes per night; P ¼ .02; LOE 1b).
Alpha-1 Adrenergic Antagonist þ PDE5 Inhibitor. Kaplan
et al conducted an RCT of 62 men with LUTS suggestive
of BPE who also had erectile dysfunction.17 Patients were
randomized to receive alfuzosin, sildenaﬁl, or both for
12 weeks. Patients treated with the combination experi-
enced the greatest improvement in IPSS score (24%),
compared with 16% for alfuzosin alone and 12% for
sildenaﬁl alone. Nocturia as measured by voiding diary
was signiﬁcantly improved by both the combination and
alfuzosin alone (LOE 3).
Conclusions. The ICUD committee considered that
alpha-adrenergic antagonists can be used in conjunction
with 5-alpha reductase inhibitors (5-ARIs). Combination
therapy may be more effective than either drug used
separately (LOE 1). A combination of an antimuscarinic
and an alpha-1 adrenergic blocker signiﬁcantly reduces
the number of nocturnal micturitions over placebo (LOE
1). A combination of an antimuscarinic and an alpha-1
adrenergic blocker can improve urgency, frequency, and
nocturia severity compared with alpha-1 adrenergic
blockade alone (LOE 3). Alpha-1 adrenergic blockers
may be more effective at improving nocturia when given
with a PDE5 inhibitor (LOE 3).4 However, many of theseUROLOGY - (-), 2015studies were not originally designed with nocturia
improvement as a primary endpoint. Because these results
thus represent secondary analysis, the resulting conclu-
sions are somewhat weakened.
Recommendations. The ICUD committee considered that
alpha-adrenergic antagonists in conjunction with 5-ARIs
may be offered to men with nocturia in association with
LUTS and BPE (GOR A). Alpha-adrenergic antagonists
in conjunction with antimuscarinic drugs may be offered
to men with nocturia in association with storage LUTS
(GOR A). Alpha-adrenergic antagonists in conjunction
with PDE5 inhibitors may be offered to men with noc-
turia (GOR C).4
Anticholinergic or Antimuscarinic. Wyndaele et al18
studied the effects of ﬂexible-dose fesoterodine (no pla-
cebo control) in 516 men with OAB. By the end of the
12-week study period, patients experienced a 31%
decrease in nightly voids from 2.6 to 1.8 voids per night
(LOE 3). Rackley et al19 conducted an RCT of 850 pa-
tients assigned to receive tolterodine ER or placebo
4 hours before bed. Although tolterodine ER was effec-
tive in reducing OAB-related and severe OABerelated
nocturnal micturitions (30% and 59% reduction,
respectively) vs placebo (22% and 43%, respectively),
it was not effective for non-OAB micturitions. Chapple
et al20 studied the effects of treatment with fesoter-
odine, tolterodine, or placebo in 1135 patients with
OAB. After 12 weeks of treatment, the median
decrease in nocturnal micturitions was 23%-29%, with
no difference between treatment groups and placebo
(LOE 1).
Zinner et al21 reported the results of a 12-week multi-
center study, in which 523 patients with OAB were
randomized to receive trospium chloride or placebo. After
12 weeks of treatment, patients in the treatment group
reported a reduction of 0.47 voids per night vs 0.29 voids
per night for placebo (P <.05; LOE 1).5
Table 2. ICUD-SIU recommendations regarding the clinical assessment of nocturia
Assessment Tool ICUD Committee Notes
Questionnaires and diaries Generic (eg, IPSS) IPSS is a generic LUTS-related questionnaire
which includes a question regarding nocturia
that has not been speciﬁcally validated.
Subject to recall bias.
Disease speciﬁc (eg, ICIQ N-QoL) ICIQ N-QoL questionnaire has been validated
as a symptom-speciﬁc QoL measure.
FVC Chart that is based on patient-recorded
volumes and times of micturition over a
minimum of 24 h. Essential to explore
underlying conditions.
Bladder diary Combines FVC data with additional relevant
information, such as pad usage or degree
of urgency.
History and physical Medical history Should thoroughly describe nocturia, as well
as other LUTS. Must rule out urologic causes
of decreased bladder capacity and underlying
medical conditions, as many of these
are treatable.
Physical examination Neurologic, cardiac, and abdominal
examinations are all critical.
Investigations Urinalysis Not speciﬁc to nocturia but allows for the
evaluation of possible causative conditions
such as urinary tract infection, malignancy,
or diabetes.
PVR Incomplete bladder emptying reduces functional
capacity and may lead to nocturia. Treatment
should aim at underlying etiology, although
no studies speciﬁcally support routine
measurement of PVR in patients with nocturia.
Uroﬂowmetry Not speciﬁc to nocturia but may aid
LUTS assessment.
Transabdominal ultrasonography Noninvasive option for the assessment
of the prostate.
Urodynamics Cystometry not routinely recommended.
Blood chemistry examination Useful for speciﬁc conditions such as chronic
kidney disease (serum creatinine) and
diabetes (glucose and hemoglobin A1c).
Radiologic examination Not routinely recommended.
Cystoscopy Not routinely recommended.
FVC, frequency-volume chart; ICIQ, International Consultation on Incontinence Questionnaire; ICUD, International Consultations on Uro-
logical Diseases; IPSS, International Prostate Symptom Score; LUTS, lower urinary tract symptoms; N-QoL, nocturiaequality of life; PVR,
postvoid residual; QoL, quality of life; SIU, Societe Internationale d’Urologie.Conclusions. The ICUD committee considered that
antimuscarinic drugs can signiﬁcantly reduce the number
of nocturnal micturitions vs placebo (LOE 1). Anti-
muscarinic drugs are more effective than placebo at
reducing OAB-related micturitions but not non-OAB
nocturnal micturitions (LOE 1). Antimuscarinic drugs
are not effective for reducing nocturia in NP (LOE 1).4
Recommendations. The ICUD committee considered that
antimuscarinic drugs can be offered to men with OAB-
related and severe OABerelated nocturnal micturitions
with suitable counseling in regard to potential adverse
effects (GOR A). Antimuscarinic drugs should not be
offered to men with NP and no urinary urgency symptoms
(GOR B).4
Antidiuretic Pharmacotherapy. In a systematic review of
13 trials of desmopressin for the treatment of nocturia,
Zong et al22 reported that desmopressin effectively6extends the duration of the ﬁrst sleep period. Sleep
quality improved and nocturnal voids also decreased
(LOE 1).
Van Kerrebroeck23 reported the results of the Noctopus
trials, a set of 3 short-term RCTs of desmopressin for the
treatment of nocturia. At 12-month follow-up, among
>1000 patients, 67% experienced a signiﬁcant reduction
in nocturnal voids vs placebo (LOE 1).
Weiss et al conducted a 4-week RCT of 757 patients
with nocturia who were randomized to receive various
doses of desmopressin oral disintegrating tablet or pla-
cebo.24 Signiﬁcant reductions in nocturnal voids were
seen with the 50- and 100-mg doses (P <.05). Transient
clinically signiﬁcant hyponatremia (Na <125 mmol/L)
occurred in 7 patients over the age of 65 years (LOE 1).
Conclusions and Recommendations. The ICUD committee
considered that desmopressin can decrease the frequency
of nocturnal voids and decrease nocturnal diuresis (LOEUROLOGY - (-), 2015
1). However, many of the evaluated studies used a dose
titration phase, which may represent a source of bias.25
Clinically signiﬁcant hyponatremia (serum
Na <125 mmol/L) is a rare but serious event; patients
over the age of 65 years are at greater risk (LOE 1).
Desmopressin can be prescribed to decrease nocturnal
diuresis and night-time frequency in men (GOR A).
Owing to the risk of hyponatremia, serum sodium testing
is essential when starting desmopressin to exclude low
sodium levels, particularly in patients over the age of 65
years (GOR A).4
Diuretic Pharmacotherapy. Reynard et al26 conducted
an RCT of 49 men with NP who were randomized to
receive furosemide or placebo 6 hours before sleep. Pa-
tients in the treatment group experienced a decrease of
0.5 voids per night vs 0 voids per night for placebo,
suggesting that men with NP may beneﬁt from timed
diuretic therapy (LOE 2).
Pederson and Johansen reported the results of an RCT
of 28 patients with nocturia 2 voids per night who
received late-afternoon bumetanide or placebo.27 A
decrease of 4 nightly voids per week was seen in the
treatment group only after excluding the 10 patients with
benign prostatic hyperplasia (LOE 3).
Conclusions. The ICUD committee considered that men
with NP may beneﬁt from diuretic therapy with furose-
mide 6 hours before sleep (LOE 2; GOR B). Bumetanide
may reduce number of nocturnal micturitions but is not
beneﬁcial in men with BPE (LOE 3; GOR C).4
Botulinum Toxin. In a study by Chapple et al,28 intra-
vesical injection of onabotulinum-A achieved a reduc-
tion in nocturia (LOE 2); the study population was
predominantly women, and data were not given sepa-
rately for men. In a pilot study of 10 patients, Hamidi
Madani et al29 used intraprostatic botulinum toxin in
men with LUTS suggestive of BPE who had failed med-
ical therapy and were poor surgical candidates. Nocturia
decreased from 4.1 voids per night before injection to 2.4
voids per night after injection (P <.001; LOE 3).
Conclusions and Recommendations. The ICUD committee
considered that botulinum toxin can reduce the number of
nocturnal micturitions in patients who fail oral medical
therapy and who are not surgical candidates (LOE 3) and
therefore can be offered as a treatment option in this group
of patients. Owing to counseling related to unlicensed use,
very limited evidence base and potential need for self-
catheterization is mandatory (GOR C).4 More evidence
is needed before botulinum toxin for therapy of nocturia
can be recommended in other contexts (GOR C).
Nonsteroidal Anti-inﬂammatory Agents. Shin et al
sought to evaluate the effect of nonsteroidal anti-
inﬂammatory agents (NSAIDs) on nocturia by assigning
40 patients to therapy with either loxoprofen þ alpha-
blocker þ 5-ARI vs alpha blocker þ 5-ARI.30 AtUROLOGY - (-), 20153-month follow-up, the treatment group which received
additional NSAID experienced a greater reduction in
nocturia (1.5  0.9 vs 1.1  0.9; P ¼ .034). However,
at 6- and 12-month follow-up, that group also reported an
increased incidence of gastrointestinal side effects
(LOE 3).
Falahatkar et al31 performed an RCT of 80 men with
nocturia with BPE who were assigned to treatment with
celecoxib or placebo. At 1-month follow-up, men in the
celecoxib group reported a decrease in nocturnal fre-
quency from 5.17 to 2.5 voids per night (P <.001) as
compared with no statistically signiﬁcant decrease in the
placebo group (LOE 3).
Conclusions and Recommendations. The ICUD committee
considered that loxoprofen sodium may reduce nocturia
for up to 3 months but should not be continued long term
because of potential adverse effects (LOE 3). Celecoxib
may reduce nocturia in men with BPE (LOE 3). More
evidence is needed before NSAID therapy can be rec-
ommended for therapy of nocturia (GOR C).4Surgical Interventions for Benign Prostatic
Enlargement
Van Dijk et al32 retrospectively analyzed 1258 men who
had undergone various treatments for LUTS suggestive of
BPE, including watchful waiting, alpha-blockers, tran-
surethral resection of prostate (TURP), and transurethral
needle ablation. After 6-12 months of follow-up, the
various modalities improved nocturia by 7%, 17%, 75%,
and 32%, respectively (LOE 3).
Schatzl et al33 prospectively studied a cohort of 95 men
with BPE who were nonrandomized to treatment with
TURP, transurethral needle ablation, high-intensity
focused ultrasound, visual laser ablation, or transurethral
electrosurgical vaporization. All modalities other than
visual laser ablation resulted in signiﬁcant reductions in
nocturia frequency (LOE 3).
Simaioforidis et al34 randomized 66 men with LUTS
suggestive of BPE to receive TURP or tamsulosin. At
3-month and 1-year follow-up, TURP was more effective
than tamsulosin in reducing the number of nocturnal
awakenings, IPSS, ICIQ-Nocturia, and ICIQeNocturia-
QoL scores (LOE 2).
Conclusions. The ICUD committee considered that
BOO-reducing procedures using various modalities of
intervention can reduce the number of nocturnal mic-
turitions (LOE 3). TURP is more effective than tamsu-
losin for treatment of BPE-related nocturia (LOE 3).4
Recommendations. The ICUD committee considered that
BOO-reducing procedures may improve nocturia in some
patients with voiding LUTS and BOO who fail medical
therapy and who are good surgical candidates (GOR C).
Surgery for relief of BOO is not indicated for management
of patients whose primary complaint is nocturia (GOR
C). Comprehensive evaluation of the cause(s) of nocturia7
is essential before contemplating a surgical approach
(GOR C). Patients must be warned of potential nonre-
sponse of nocturia and of risks associated with surgery
(GOR C).4
Phytotherapy
In a Cochrane review of 30 RCTs of saw palmetto extract
for the treatment of nocturia; Tacklind et al35 found no
signiﬁcant difference between saw palmetto and placebo
(LOE 1). Barry et al36 conducted an RCT of 369 men
with nocturia who were treated with saw palmetto or
placebo. No difference in nocturia outcomes was seen at
24- or 48-week follow-up (LOE 2).
Wilt et al37 reported the results of a Cochrane review
of 18 RCTs of Pygeum africanum for the treatment of men
with nocturia. Although P africanum was not directly
compared with drug therapy, it did appear to reduce
nocturia vs placebo by 19% (LOE 1). Wilt et al38 also
reviewed the literature on Cernilton, a rye-grass pollen
derivative, which has been used to treat nocturia.
Treatment with Cernilton appeared to relieve nocturia
more effectively than did placebo and other
phytotherapy-based active controls (LOE 1).
Conclusions and Recommendations. The ICUD committee
considered that Serenoa repens (saw palmetto) does not
reduce the number of nocturnal micturitions compared
with that of placebo (LOE 1). P africanum (African plum
tree) and Cernilton (rye pollen) reduce the number of
nocturnal micturitions when compared with that of pla-
cebo (LOE 1). S repens should not be prescribed for
treatment of nocturia (GOR A). P africanum and Cer-
nilton can be offered as an option for treating nocturia
(GOR A).4
Agents to Promote Sleep
Kaye39 described personal experience with oxazepam for
the self-treatment of nocturia. Nocturia severity was
reduced by 63%, but nocturnal urine volume was un-
changed (LOE 3). Takami et al conducted a cross-
sectional study of 123 patients assigned to triazolam,
nitrazepam, or control groups for the treatment of noc-
turia.40 The primary inﬂuence of therapy appeared to
entail improving return to sleep after each episode, for
which nitrazepam was most effective (LOE 3).
Drake et al41 reported the results of an RCT of 20 men
with BOO and nocturia who were assigned to treatment
with bedtime melatonin or placebo. Melatonin and pla-
cebo caused a decrease in nocturia of 0.32 and 0.05 episodes
per night, respectively (P¼ .07). In this study, the presence
of a subgroup of “responder” patients was identiﬁed.
Conclusions and Recommendations. The ICUD committee
considered that hypnotics do not appear to inﬂuence
nocturia directly but may be used to aid return to sleep
(LOE 3, GOR C). Potential adverse effects of hypnotics
should be considered. Melatonin may reduce number of
nocturnal voids (LOE 2, GOR C).48CONCLUSION
The complex nature of nocturia has led to a signiﬁcant
proliferation in clinical studies that explore its epidemi-
ology, pathophysiology, assessment, and treatment. In an
attempt to grade these studies in a standardized way, the
ICUD-SIU Consultation on LUTS recently assigned
LOEs and GORs to the most inﬂuential research in this
ﬁeld. This Consultation’s recommendations provide
contemporaneous expert consensus on this topic and offer
practical recommendations for urologists who are faced
with nocturia in everyday practice.
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